Tracer library / [90Y]Y-DOTATATE
[90Y]Y-DOTATATE
Also written as DOTATATE; DOTA-TATE; dotatate
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- DOTA-conjugated somatostatin analog
- Target / mechanism
- Somatostatin receptor (SSTR) binding PMID 41356201
- Clinical application
- Peptide receptor radionuclide therapy for SSTR-expressing neuroendocrine neoplasms PMID 41356201
- Theranostic pair
- [68Ga]Ga-DOTATATE
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | >97% | DOTATATE | 26443981 2016 Nucl Med Commun novel, self-shielded modular radiosynthesis system for fully automated preparation of PET and therapeutic radiopharmaceuticals |
| Manual synthesis n/a | — | — | — | >95% | DOTA-TATE | 30770227 2019 Nucl Med Biol A two-step radiochemical separation procedure based on selective precipitation of 90Y under alkaline conditions from 90Sr/90Y equilibrium mixture was developed. |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.2025 · Front Endocrinol (Lausanne) · Prospective, multicentre · Phase III
- Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?2020 · Endokrynol Pol · Multicentre
- Adverse Events of Radioligand Therapy in Patients with Progressive Neuroendocrine Neoplasms: The Biggest Eastern European Prospective Study.2024 · Cancers (Basel) · Prospective
- Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.2024 · Endocrine · Retrospective
- Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.2019 · J Nucl Med · Retrospective
- Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.2025 · Clin Nucl Med · Clinical study
- Possible changes in glucose metabolism induced by radioligand therapy in patients with neuroendocrine neoplasms.2024 · Endokrynol Pol · Clinical study
- Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.2022 · Nucl Med Rev Cent East Eur · Clinical study
- Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.2014 · Eur J Nucl Med Mol Imaging · Clinical study · Phase II
- Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.2016 · J Neurosurg · Case report
Show all 11 clinical studies
Need this precursor?We can point you to suppliers for [90Y]Y-DOTATATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 8 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Cu-64, Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 41356201: 'The DOTA-conjugated somatostatin analogs DOTATOC and DOTATATE were labeled with 68Ga for SSTR PET imaging and either 177Lu or 90Y for IA-PRRT'.